Risk of Parkinson disease in carriers of Parkin mutations: Estimation using the kin-cohort method

Archives of Neurology

Volumn 65, Issue 4, 2008, Pages 467-474

  Wang, Yuanjia ^a   Clark, Lorraine N ^b,d   Louis, Elan D ^a,b,c,d   Mejia Santana, Helen ^c   Harris, Juliette ^d   Cote, Lucien J ^c,d   Waters, Cheryl ^d   Andrews, Howard ^a,c   Ford, Blair ^d   Frucht, Steven ^d   Fahn, Stanley ^d   Ottman, Ruth ^a,c,d,f   Rabinowitz, Daniel ^e   Marder, Karen ^b,c,d  

^a Mailman School of Public Health ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d Columbia University ^*  (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARKIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE DUPLICATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ONSET AGE; PARKINSON DISEASE; PENETRANCE; POINT MUTATION; PRIORITY JOURNAL; RELATIVE; SIBLING;

ADULT; AGE FACTORS; AGED; ALLELES; CASE-CONTROL STUDIES; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PENETRANCE; PROBABILITY; PROTEIN-SERINE-THREONINE KINASES; RISK ASSESSMENT;

EID: 42249091077     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.4.467     Document Type: Article

References (27)

1. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605- 608.
2. Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord. 2004;19(10):1146-1157.
3. Lücking CB, Durr A, Bonifati V, et al; French Parkinson's Disease Genetics Study Group. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000;342(21):1560-1567.
4. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology. 2002;58(8):1239-1246.
5. Abbas N, Lucking CB, Ricard S, et al; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet. 1999;8(4):567-574.
6. Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain. 2003;126(pt 6):1271-1278.
7. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol. 2003;54(2):176-185.
8. Foroud T, Uniacke SK, Liu L, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60(5):796-801.
9. Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003;53(5):624-629.
10. Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006;63(6):826-832.
11. Wacholder S, Hartge P, Struewing JP, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol. 1998;148(7):623-630.
12. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-1408.
13. Dekker MC, Bonifati V, Van Duijn CM. Parkinson's disease: piecing together a genetic jigsaw. Brain. 2003;126(pt 8):1722-1733.
14. Marder K, Levy G, Louis ED, et al. Familial aggregation of early- and late-onset Parkinson's disease. Ann Neurol. 2003;54(4):507-513.
15. Gail MH, Pee D, Benichou J, Carroll R. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs. Genet Epidemiol. 1999;16(1):15-39.
16. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease. Neurology. 2003;61(1):18-23.
17. Levy G, Louis ED, Mejia-Santana H, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol. 2004;61(7):1033-1039.
18. Clark LN, Afridi S, Karlins E, et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol. 2006;63(4):548-552.
19. Fahn S, Elton RL; Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163, 293-304.
20. Pigullo S, De Luca A, Barone P, et al. Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord. 2004;10(6):357-362.
21. Clark LN, Haamer E, Mejia-Santana H, et al. Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov Disord. 2007;22(7):932-937.
22. West A, Periquet M, Lincoln S, et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet. 2002;114(5):584-591.
23. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006;67(10):1786- 1791.
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons, Inc; 1980.
25. Kay DM, Moran D, Moses L, et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol. 2007;61 (1):47-54.
26. Kann M, Jacobs H, Mohrmann K, et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol. 2002;51(5):621-625.
27. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst. 2002;94(16):1221-1226.